The interface between antibiotic resistance and virulence in staphylococcus aureus and its impact upon clinical outcomes

Clinical Infectious Diseases

Volumn 53, Issue 6, 2011, Pages 576-582

  Cameron, David R ^a   Howden, Benjamin P ^b,c   Peleg, Anton Y ^a,d,e  

^a MONASH UNIVERSITY   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CEFAZOLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINCOSAMIDE; MACROLIDE; METICILLIN; PANTON VALENTINE LEUKOCIDIN; PENICILLIN G; QUINOLONE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; SMALL COLONY VARIANT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 80052187287     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir473     Document Type: Article

References (77)

1. Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998; 6:484-8. (Pubitemid 29002881)
2. Barber M, Rozwadowska-Dowzenko M. Infection by penicillinresistant staphylococci. Lancet 1948; 2:641-4.
3. Matsuhashi M, Song MD, Ishino F, et al. Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to betalactam antibiotics in Staphylococcus aureus. J Bacteriol 1986; 167:975-80. (Pubitemid 16045033)
4. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:1549-5. (Pubitemid 30340793)
5. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3. (Pubitemid 28036828)
6. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycinresistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7. (Pubitemid 36384101)
7. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23:99-139.
8. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycinintermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51. (Pubitemid 38200128)
9. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058-60. (Pubitemid 40418318)
10. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8. (Pubitemid 32718546)
11. Dowzicky M, Talbot GH, Feger C, et al. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000; 37:57-62. (Pubitemid 30224525)
12. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-35. (Pubitemid 35231593)
13. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995; 21:1417-23.
14. Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30:368-73. (Pubitemid 30131548)
15. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 2003; 37:1453-60. (Pubitemid 37494672)
16. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171-7. (Pubitemid 30265635)
17. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9. (Pubitemid 36099097)
18. Whitby M, McLaws ML, Berry G. Risk of death from methicillinresistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001; 175:264-7. (Pubitemid 32851061)
19. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74. (Pubitemid 40445022)
20. Rozgonyi F, Kocsis E, Kristof K, Nagy K. Is MRSA more virulent than MSSA? Clin Microbiol Infect 2007; 13:843-5. (Pubitemid 47244132)
21. Schmitz FJ, MacKenzie CR, Geisel R, et al. Enterotoxin and toxic shock syndrome toxin-1 production of methicillin resistant and methicillin sensitive Staphylococcus aureus strains. Eur J Epidemiol 1997; 13:699-708. (Pubitemid 27375076)
22. Jordens JZ, Duckworth GJ, Williams RJ. Production of "virulence factors" by "epidemic" methicillin-resistant Staphylococcus aureus in vitro. J Med Microbiol 1989; 30:245-52. (Pubitemid 20023708)
23. Coia JE, Browning L, Haines L, Birkbeck TH, Platt DJ. Comparison of enterotoxins and haemolysins produced by methicillin-resistant (MRSA) and sensitive (MSSA) Staphylococcus aureus. J Med Microbiol 1992; 36:164-71.
24. Cree RG, Aleljung P, Paulsson M, et al. Cell surface hydrophobicity and adherence to extra-cellular matrix proteins in two collections of methicillin-resistant Staphylococcus aureus. Epidemiol Infect 1994; 112:307-14. (Pubitemid 24100737)
25. Vaudaux PE, Monzillo V, Francois P, et al. Introduction of the mec element (methicillin resistance) into Staphylococcus aureus alters in vitro functional activities of fibrinogen and fibronectin adhesins. Antimicrob Agents Chemother 1998; 42:564-70. (Pubitemid 28114809)
26. Ward TT. Comparison of in vitro adherence of methicillin-sensitive and methicillin-resistant Staphylococcus aureus to human nasal epithelial cells. J Infect Dis 1992; 166:400-4.
27. Duckworth GJ, Jordens JZ. Adherence and survival properties of an epidemicmethicillin-resistant strain of Staphylococcus aureus compared with those of methicillin-sensitive strains. J Med Microbiol 1990; 32:195-200. (Pubitemid 20217358)
28. Peacock JE Jr., Moorman DR, Wenzel RP, Mandell GL. Methicillinresistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain. J Infect Dis 1981; 144:575-82. (Pubitemid 12194463)
29. Hewitt JH, Sanderson PJ. The effect of methicillin on skin lesions in guinea-pigs caused by "methicillin-sensitive" and " methicillinresistant" Staphylococcus aureus. J Med Microbiol 1974; 7:223-35.
30. Mizobuchi S, Minami J, Jin F, Matsushita O, Okabe A. Comparison of the virulence of methicillin-resistant and methicillin-sensitive Staphylococcus aureus. Microbiol Immunol 1994; 38:599-605. (Pubitemid 24264886)
31. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55. (Pubitemid 30485502)
32. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8. (Pubitemid 34754172)
33. Khatib R, Saeed S, Sharma M, et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25:181-5.
34. Shorr AF, Micek ST, Kollef MH. Inappropriate therapy for methicillinresistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 2008; 36:2335-40.
35. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysisdependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-6. (Pubitemid 46079979)
36. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillinsusceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol 2009; 30:453-60.
37. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993; 25:97-108. (Pubitemid 23337269)
38. Diep BA, Stone GG, Basuino L, et al. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis 2008; 197:1523-30. (Pubitemid 351706482)
39. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009; 9:384-92.
40. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245-51. (Pubitemid 41345946)
41. Li M, Diep BA, Villaruz AE, et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci USA 2009; 106:5883-8.
42. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007; 45:1705-11. (Pubitemid 46933895)
43. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23:616-87.
44. Collins J, Rudkin J, Recker M, et al. Offsetting virulence and antibiotic resistance costs by MRSA. ISME J 2010; 4:577-84.
45. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for communityassociated MRSA. Nat Med 2007; 13:1510-4. (Pubitemid 350224240)
46. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007; 13:1405-6. (Pubitemid 350224232)
47. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41.
48. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753-9. (Pubitemid 34215075)
49. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894-9.
50. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-32. (Pubitemid 30265628)
51. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45:315-21. (Pubitemid 47101027)
52. Gillet Y, Etienne J, Lina G, Vandenesch F. Association of necrotizing pneumonia with Panton-Valentine leukocidin-producing Staphylococcus aureus, regardless of methicillin resistance. Clin Infect Dis 2008; 47:985-6.
53. Diep BA, Chan L, Tattevin P, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci USA 2010; 107: 5587-92.
54. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-39. (Pubitemid 36241308)
55. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8. (Pubitemid 38250962)
56. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47:1640-4.
57. Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinsusceptible MRSA. Antimicrob Agents Chemother 2009; 53:3447-52.
58. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997-8.
59. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200. (Pubitemid 351269157)
60. Lalueza A, Chaves F, San Juan R, et al. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J Infect Dis 2010; 201:311-2author reply 2-3.
61. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199-209. (Pubitemid 28393588)
62. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179:2557-66. (Pubitemid 27164554)
63. Howden BP, Smith DJ, Mansell A, et al. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol 2008; 8:39.
64. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104:9451-6. (Pubitemid 47185800)
65. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187:929-38. (Pubitemid 36337905)
66. Fujimoto DF, Bayles KW. Opposing roles of the Staphylococcus aureus virulence regulators, Agr and Sar, in Triton X-100-and penicillininduced autolysis. J Bacteriol 1998; 180:3724-6. (Pubitemid 29115108)
67. Abdelnour A, Arvidson S, Bremell T, Ryden C, Tarkowski A. The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model. Infect Immun 1993; 61:3879-85. (Pubitemid 23260062)
68. Novick RP, Ross HF, Projan SJ, et al. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J 1993; 12:3967-75. (Pubitemid 23282772)
69. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492-502. (Pubitemid 34415333)
70. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:3039-47. (Pubitemid 44396410)
71. Peleg AY, Monga D, Pillai S, et al. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 2009; 199:532-6.
72. Majcherczyk PA, Barblan JL, Moreillon P, Entenza JM. Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis. Microb Pathog 2008; 45:408-14. (Pubitemid 50320627)
73. Burnie J, Matthews R, Jiman-Fatami A, et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000; 31:684-9. (Pubitemid 32295487)
74. Proctor RA, von Eiff C, Kahl BC, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4:295-305.
75. Gao W, Chua K, Davies JK, et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog 2010; 6:e1000944.
76. Sendi P, Proctor RA. Staphylococcus aureus as an intracellular pathogen: the role of small colony variants. Trends Microbiol 2009; 17:54-8.
77. Proctor RA, van Langevelde P, Kristjansson M, Maslow JN, Arbeit RD. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis 1995; 20:95-102.